Claire Mazumdar Sells 15,000 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 15,000 shares of Bicara Therapeutics stock in a transaction on Monday, April 20th. The shares were sold at an average price of $23.61, for a total value of $354,150.00. Following the sale, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at $8,550,408.72. This represents a 3.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, March 18th, Claire Mazumdar sold 6,499 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.84, for a total value of $122,441.16.
• On Thursday, March 19th, Claire Mazumdar sold 6,905 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.78, for a total value of $129,675.90.
• On Friday, March 20th, Claire Mazumdar sold 1,596 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.95, for a total value of $30,244.20.
• On Monday, March 9th, Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock. The shares were sold at an average price of $19.17, for a total value of $704,804.22.
• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.75, for a total value of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.73, for a total value of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.74, for a total value of $33,469.64.

Bicara Therapeutics Price Performance

NASDAQ:BCAX traded down $0.54 during trading hours on Monday, hitting $23.47. 353,574 shares of the company’s stock traded hands, compared to its average volume of 570,129. Bicara Therapeutics Inc. has a 52 week low of $7.80 and a 52 week high of $24.25. The business’s fifty day simple moving average is $18.82 and its two-hundred day simple moving average is $17.64.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.04. On average, research analysts expect that Bicara Therapeutics Inc. will post -2.72 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Citizens Jmp restated a “market outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Wednesday, April 8th. Citigroup assumed coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating on the stock. Finally, Wedbush restated an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $28.00.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Deutsche Bank AG increased its holdings in shares of Bicara Therapeutics by 0.9% in the fourth quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock worth $2,165,000 after buying an additional 1,171 shares during the period. Legal & General Group Plc increased its holdings in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares during the period. Mariner LLC increased its holdings in shares of Bicara Therapeutics by 3.0% in the fourth quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after buying an additional 1,902 shares during the period. Invesco Ltd. increased its holdings in shares of Bicara Therapeutics by 13.2% in the second quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock worth $157,000 after buying an additional 1,962 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Bicara Therapeutics in the fourth quarter worth about $45,000.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.